Veeva Systems is overvalued, with modest ~10% growth & high valuation multiples. Read why I recommend a sell rating on VEEV ...

KeyBanc lowered the firm’s price target on Veeva (VEEV) to $250 from $260 and keeps an Overweight rating on the shares. Into Q1 earnings, the ...

Veeva Systems experienced a 6% price increase last week, potentially propelled by its recent partnership with Flatiron Health. This collaboration aims to streamline clinical trial processes ...

Cloud CTMS software to improve research site efficiency and integrate seamlessly with sponsors ...

Veeva Systems (VEEV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance ...

CHICAGO – 1 April, 2025 - EVERSANA, a global provider of commercial services to the life sciences industry, today announced it has been named an official Veeva AI Partner ... industry-sponsored portal ...

Vertex Pharmaceuticals continues to develop therapies where there is a need. Veeva Systems has a long runway for growth in its niche of the cloud market. Equity markets have been seesawing for the ...

To thrive in this environment, pharma needs to move from ad-hoc and reactionary digital transformation to long-term ‘digital excellence’, says Veeva’s Sebastien Noel. COVID has seen pharma ...

who’s senior manager of CRM events management strategy at Veeva. “Before COVID, pharma events were mainly face-to-face. There’s now a need to find different ways of interacting with HCPs.” ...